前列腺癌PCNA及AgNOR的表达及临床意义

PCNA AGNOR AND EXPRESSION IN PROSTATIC CARCINOMA CLINICAL VALUE

  • 摘要: 应用免疫组化(ABC法)和银染技术检测10树前列腺癌和20例前列腺增生患者增殖细胞核抗原(PCNA)和核仁组成区嗜银蛋白(AgNOR)数量变化.结果显示PCNA阳性检出率及AgNOR计数有显著差异(P<0.01).且随肿瘤分级增高而增高.随访资料显示PCNA强级(~)者,AgNOR计数高者预后明显低于PCNA弱级(~),AgNOR计数低者.结果提示PCNA,AgNOR可作为前列腺良恶性肿瘤鉴别诊断指标之一,并且与前列腺癌恶性程度有关,对推测预后具有重要参考价值。

     

    Abstract: Expression of proliferating cell nuclear antigen (PCNA) and number of nucleolarga-nizer region-associated proteins (AgNOR) were detected in 10 cases of prostatic carcinoma and 20 casesof benign hyperplasia tissue using the immunohistochemical method and silver-staining technique. The re-sults showed that the proportion of PCNA posttive cell and counts of AgNOR had significant differentionbetween malignant and benign tissue (P0. 01 ). and were increased with grade Prognosis of the patientWith high PCNA (50%) and high AgNOR counts (4. 0) was worse than those with PCNA indexbelow (50% ) and AgNOR counts below. Our findings suggest that PCNA and AgNOR might be usedto differentiate benign tumors from malignant, and have a reference value on evaluating the prognosis ofprostatic carcinoma.

     

/

返回文章
返回